Get the Stockscreener App
1,090.16
1.07%
11.64
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,090.16, with a volume of 1.93M.
It is up +1.07% in the last 24 hours and up +1.26% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,078.52
Open:
$1078.52
24h Volume:
1.93M
Relative Volume:
0.56
Market Cap:
$975.64B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
53.92
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+5.52%
1M Performance:
+1.26%
6M Performance:
+40.39%
1Y Performance:
+44.57%
1-Day Range:
$1,071.74
$1,095.48
1-Week Range:
$1,015.96
$1,095.48
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,090.07 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.94 | 525.25B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
217.97 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.20 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.30 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Shines Amid Healthcare Sector's Underperformance - GuruFocus
Eli Lilly and Co's Options Frenzy: What You Need to Know - Benzinga
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
Vest Financial LLC Buys 2,178 Shares of Eli Lilly and Company $LLY - MarketBeat
Bey Douglas LLC Reduces Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Oncology Ambitions Gain Momentum with Key FDA Designation - AD HOC NEWS
Nvidia CEO to Lilly CEO: You were running around the forest … - MedCity News
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.6%Time to Buy? - MarketBeat
Vital Signs: Unwrapping J&J's $100 billion ambition - FirstWord Pharma
Why Eli Lilly (LLY) Stock Is Up Today - Finviz
Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine - FinancialContent
Eli Lilly’s Oncology Pipeline Gains Momentum with Key Regulatory Designation - AD HOC NEWS
Stock Yards Bank & Trust Co. Acquires 1,197 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - The AI Journal
First-movers respond to biopharma herding into hot targets - Endpoints News
Rakuten Investment Management Inc. Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Has $137.37 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Joel Isaacson & Co. LLC Acquires 3,976 Shares of Eli Lilly and Company $LLY - MarketBeat
Recludix Tackling Inflammatory Diseases with Backing From Eli Lilly - sdbj.com
Middleton & Co. Inc. MA Has $9.24 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Dynasty Wealth Management LLC Sells 3,206 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Faces Regulatory Delay as Key Drug Approval Pushed to 2026 - AD HOC NEWS
Abivax CEO Dismisses Rumors of Eli Lilly (LLY) Takeover as ‘Noise’ - TipRanks
Eli Lilly (LLY) Denies Acquisition Talks with Abivax (ABVX) - GuruFocus
Guggenheim Lowers Eli Lilly and Company (NYSE:LLY) Price Target to $1,161.00 - MarketBeat
Bernstein reiterates Outperform rating on Eli Lilly stock with $1,300 price target - Investing.com
New GCGR agonists disclosed in Eli Lilly patent - BioWorld MedTech
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid - Reuters
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,161 - Futubull
Eli Lilly (LLY) Receives FDA Breakthrough Designation for New Ca - GuruFocus
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer | Eli Lilly and Company - Eli Lilly
FDA grants Breakthrough status to drug for hard-to-treat ovarian cancer - Stock Titan
Abivax CEO dismisses ’noise’ around rumored Eli Lilly bid By Reuters - Investing.com
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data - Investing.com
Assessing Eli Lilly (LLY) Valuation After Recent Choppy Trading And GLP 1 Growth Expectations - Yahoo Finance UK
Eli Lilly (LLY) Faces Competition from Structure Therapeutics' P - GuruFocus
Eli Lilly Faces Headwinds Amid Regulatory Delay and Legal Challenge - AD HOC NEWS
Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine - FinancialContent
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever - Finviz
Compounder sues Lilly and Novo for suppressing GLP-1RA competition - Pharmaceutical Technology
Eli Lilly's Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial - Finviz
Mizuho Markets Americas LLC Invests $10.68 Million in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly price tries to recoup some lossesForecast today19-01-2026 - Economies.com
Eli Lilly's (NYSE:LLY) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth - Futubull
Eli Lilly vs. Novo Nordisk: Which Stock Offers More Upside? - CoinCentral
OpenAI Backed Chai Discovery Partners With Eli Lilly to Accelerate Biologics Discovery - AIM Media House
Chai Discovery Strikes Eli Lilly AI Drug Deal - findarticles.com
Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue - Intellectia AI
Florida Trust Wealth Management Co Purchases 2,589 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 10% Owner |
Jan 05 '26 |
Sale |
1,085.01 |
1,390 |
1,508,165 |
92,189,126 |
| LILLY ENDOWMENT INC | 10% Owner |
Dec 29 '25 |
Sale |
1,085.04 |
3,593 |
3,898,531 |
92,190,516 |
| LILLY ENDOWMENT INC | 10% Owner |
Dec 24 '25 |
Sale |
1,085.17 |
2,629 |
2,852,920 |
92,194,109 |
| LILLY ENDOWMENT INC | 10% Owner |
Dec 23 '25 |
Sale |
1,085.04 |
240 |
260,409 |
92,196,738 |
0.58%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):